| Name | Title | Contact Details |
|---|---|---|
Sarah Whipple |
VP, Legal and Chief Compliance Officer | Profile |
Molly Shea |
Head of Regulatory Affairs | Profile |
Henry Gu |
Vice President, Chief Intellectual Property Counsel | Profile |
Andrea Paul |
Vice President, Legal - Corporate and Securities | Profile |
Laura Graham |
Director, Corporate Counsel | Profile |
Kriya is a next-generation gene therapy company focused on designing and developing transformative new treatments for highly prevalent and severe chronic diseases.
Zynerba (NASDAQ: ZYNE) is dedicated to improving the lives of people with rare and near rare neuropsychiatric disorders where there is a high unmet medical need by pioneering the development and commercialization of next-generation pharmaceutically-produced cannabinoid therapeutics formulated for transdermal delivery. Cannabinoids interact with specific receptors throughout the body to produce pharmacologic effects, primarily in the CNS and immune systems. Transdermal delivery has the potential to reduce adverse effects associated with oral dosing because it allows the drug to be absorbed through the skin directly into the bloodstream, avoiding the gastrointestinal tract and lessening the opportunity for GI-related adverse events. It also avoids first-pass liver metabolism, potentially enabling lower dosage levels of active pharmaceutical ingredients with a higher bioavailability and an improved safety profile. Zynerba`s lead patent-protected product candidate in clinical development is ZYN002: ZYN002 is the first and only pharmaceutically-produced cannabidiol (CBD) formulated as a permeation-enhanced gel for transdermal delivery. Through a proprietary combination of our pharmaceutically-produced CBD and permeation enhancers, we believe we can effectively deliver CBD through the layers of the epidermis and into the circulatory system. The company is currently assessing ZYN002 in Fragile X syndrome and certain adult and pediatric refractory epilepsies. These include adult refractory focal epilepsy and developmental and epileptic encephalopathies (DEE), a heterogeneous group of rare and ultra-rare epilepsy syndromes associated with severe cognitive impairment and behavioral disturbances.
Woodcock Washburn is a Philadelphia, PA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Vitalcor is a Westmont, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Helping protect life through fundamental breakthroughs in vaccine adjuvant design and manufacturing.